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Artemisinin: From Chinese Herbal Medicine to  
Modern Chemotherapy
Malaria is a disease that has blighted 
humankind since early times. The first 
antimalarial treatment available to Europeans 
was the dried bark of the cinchona tree 
from Peru. The main problem in its use was 
adulteration by other material. The ‘active 
principle’ was first extracted in 1820 and named 
quinine. It was found to be a more powerful 
and reliable drug than cinchona bark. Once 
its chemical structure had been determined, 
it was possible to synthesize substances 
chemically related to quinine that were 
equally powerful but could be manufactured 
industrially. Mepacrine (atabrine) was amongst 
the most successful, but had adverse side 
effects. To avoid these side effects, further 
chemical modification gave chloroquine, a 
highly successful drug. This sequence is a 
common way of converting an herbal remedy 
into a modern-style chemical drug. It parallels, 
to some extent, the process of potentiation 
common in traditional herbal medicine. By the 
1970s, drug resistance had developed  
with chloroquine. To find and develop a new 
antimalarial drug that worked on an entirely 
different pharmacological principle, Chinese 
scientists turned to their herbal compendia 
(ben cao) and found that Artemisia annua (qing 
hao) was frequently mentioned as a treatment 
for intermittent fever. Whether, in view of the 
distinctive doctrines of Chinese medicine, 
it should be possible to extract an active 
principle as described above is discussed. After 
a very careful reading of the procedure given 
for the use of qing hao, an active substance, 
artemisinin, was extracted. Artemisinin has 
a truly remarkable chemical structure, and 
chemical modification produced artesunate, 
the drug of choice. To prevent the development 
of resistance, artesunate is used in combination 
with other antimalarial drugs. Modern 
pharmacology has largely ignored that other 
substances in artemisia and the cinchona bark 
may contribute to their therapeutic effect. This 
matter is also discussed.
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Introduction
Malaria is a disease that has been with humankind since 
the dawn of civilization. It has been suggested that more 
humans have died of malaria than any other disease in 
the history of the world (Packard 2007). Malaria is caused 
by the presence of the parasite Plasmodium in the blood-
stream. There are five species of Plasmodium that give rise 
to malaria, of which P. falciparum is the most serious as it 
can cause blood clots to form in the brain. This condition 
is known as cerebral malaria and can be the cause of death. 
One of the most characteristic symptoms of all types of 
malaria is an intermittent fever, and the interval between 
bouts corresponds to the reproductive cycle of the partic-
ular species of Plasmodium present in the patient’s blood.
The vector that carries the parasite from an infected 
person to a new person is the female Anopheles mosquito, 
as she requires human blood for the nourishment of her 
eggs. Thus, any attempt to counter malaria in both the 
individual and the community must include a drug with 
directed toxicity towards Plasmodium and a means of 
controlling the mosquito. Here we are concerned with only 
the former. Malaria is a serious health problem in mosqui-
to-inhabited parts of the world and is thought to cause the 
death of around a million children a year in Africa since 
their immune system is not fully developed (Maitland 
2016). Those living permanently in malarious areas do 
acquire some immunity as they mature.
Early Treatment for Malaria
Before the seventeenth century, Europeans tried a number 
of herbal remedies, but none were effective. The first 
success came with the Spanish colonization of South 
America. Jesuit missionaries in Peru brought back to 
Europe the bark of the fever tree (Cinchona spp.) (Rocco 
2003). They likely learned of its healing properties from 
Inca herbalists. It proved to be an effective remedy for 
malaria; since the disease occurred all over central and 
southern Europe, the effect of its arrival was dramatic and 
meant that all who could afford the bark stood a chance of 
recovering from malaria. It also allowed people to explore 
and colonize malarious regions of Africa that previously 
had been left alone. Demand for cinchona bark (sometimes 
known as ‘Jesuits’ powder’) soon outstripped supply. One 
reason for this was that removing the bark often killed the 
cinchona tree, and the search for more bark took hunters 
to more and more remote parts of Peru until, eventually, 
the supply dried up. The British government managed to 
obtain seeds of the cinchona tree around 1850, raised seed-
lings at Kew Botanic Gardens in London and established 
plantations in India. The trees did not flourish. The Dutch 
authorities obtained some of the seeds and were much more 
successful with plantations in Java, and this eventually 
became the chief source of cinchona bark (Jercho 1993).
Extraction of Quinine
One of the main drawbacks with bark as a medicine is the 
possibility of adulteration. Unscrupulous traders substi-
tuted bark from other trees, with no curative properties, 
for cinchona bark. By the beginning of the nineteenth 
century, organic chemistry had developed a number of 
experimental procedures that allowed two French chem-
ists to extract the active principle—that is, the substance 
or substances amongst the dozens in the bark responsible 
for cure of malaria—from the Peruvian bark (Pelletier and 
Caventou 1820). The active principle in cinchona bark is 
composed of two substances, which are both alkaloids: 
quinine and cinchonine. The former is easier to isolate and 
became the world’s first antimalarial drug. Thus quinine 
(Figure 1) was born and rapidly became the drug of choice, 
rather than the crude bark, for the treatment of malaria. 
This is an early example of the transformation of an herbal 
remedy into a modern-style chemical drug. 
The curative properties of Peruvian bark were always 
uncertain, even if the bark was authentic, because the 
amount of quinine it contained varied according to the 
season of harvesting. Extraction of the active principle 
led not only to a more powerful but also a more reliable 
drug as it was possible, by means of an assay, to assess 
its purity. Quinine is still used today for the treatment of 
malaria. The quinine story, of extraction and purification 
from an herbal source, is a frequent sequence of events 
in the development of a new drug from a medicinal herb. 
The process may also be seen as parallel to that used in 
biomedicine for the potentiation of an herbal remedy. A 
further example is the use of powdered foxglove leaves 
in the treatment of dropsy. They were the recommended 
remedy for centuries, and it was not until the 1920s that 
the glycoside responsible for its effect was extracted, 
purified, and identified (Smith 1930). Digoxin is now used 
in preference to the dried leaves.
Synthetic Antimalarial Drugs
The German effort during World War I was severely 
compromised by poor access to quinine since fighting 
took place in malarious parts of Europe, such as Italy and 
the Balkans. During the 1920s, German chemists studied 
compounds that retained some aspects of the chemical 
structure of quinine but were much simpler and could be 
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prepared in the laboratory and then in a chemical factory. 
Many of them had quinine-like curative properties. A 
particularly successful one was mepacrine, or atabrine 
(Figure 1B). It was used extensively by United States (US) 
troops during the war in the Pacific, and was found to be 
superior to quinine as an antimalarial drug (Sneader 1996). 
By 1945, the Americans had produced an even better, 
chemically related, antimalarial drug: chloroquine (Surrey 
and Hammer 1946; see Figure 1C). It was inexpensive to 
make and showed few adverse side effects. For a number 
of years, it was the drug of choice in the treatment of most 
forms of malaria.
The sequence of events described above (synthesizing 
compounds chemically related to the active principle as 
extracted from the herb, thus leading to a more powerful 
and effective drug) is a common part of modern drug 
development. The lead comes not from the wisdom of 
modern pharmacologists but rather from a humble herbal 
cure. Chloroquine can be seen as the climax of a series 
of chemical modifications of the quinine molecule, all 
yielding a better drug than that supplied by nature.
Project 523
The triumph of chloroquine did not last for long. By the 
late 1960s, its efficacy as an antimalarial drug showed a 
significant decline; the malarial parasite had mutated 
in some way as to resist the toxicity of chloroquine. 
This is the parasite showing a characteristic of all living 
things, namely the wish to live. Resistance caused grave 
concern in the West and removed any chance of success 
in attempts to eradicate malaria worldwide. It was also 
causing concern in a part of the world of which, at that 
time, we knew very little: China.
As China went through a period of great tumult and 
cruelty during the Cultural Revolution (1966-1976), 
Chinese soldiers were fighting a war in the jungles of 
Vietnam against the South Vietnamese. It was a highly 
malarious region and soldiers, normally free of malaria 
because they took chloroquine as a prophylactic, started 
to develop symptoms of the disease. Without effective 
malarial chemotherapy, success in jungle warfare is almost 
impossible. As a result, the Chinese government, led by 
Mao Zedong at the prompting of Zhou Enlai, set up an 
extensive research program (known as Project 523) to find 
an alternative to chloroquine (Li 2007: 5-20). By 1967, over 
five hundred scientists from sixty institutions had been 
recruited, and the group included chemists, pharmacolo-
gists, entomologists, and doctors. 
Although Mao’s aim was to modernize China, he insisted 
that traditional Chinese medicine was a ‘great treasure 
house,’ a phrase made famous by its inclusion in the ‘The 
Little Red Book.’ He insisted that it should be taken seri-
ously in spite of the views of some Chinese scientists that 
it should be relegated to the waste bin. Accordingly, part 
of the work of Project 523 was to see if there was anything 
in traditional Chinese herbal medicine that would give a 
lead to a new antimalarial drug in the way that Peruvian 
bark had led to quinine. Herbs were harvested in the 
traditional way and subjected to extraction and analysis. 
The extract was then tested against murine malaria. To 
see which herbs should be tested, it was necessary to know 
how malaria was named in the old herbals. This matter has 
been examined authoritatively by Hsu (2006a, 2009). The 
term ‘intermittent fever’ (a hallmark symptom of malaria) 
occurs in several texts and, although not all sufferers from 
malaria display this symptom, it is so characteristic of the 
disease that we may say that many people experiencing 
intermittent fever had what we now call malaria. Any herb 
said to treat intermittent fever was felt worthy of consid-
eration, and this is what the scientists on Project 523 set 
out to do (Hsu 2014).
The Doctrines of Chinese Medicine
We now come to a more complex problem peculiar to 
the Chinese situation. In Chinese medicine, herbs were 
prescribed according to a highly organized system, seeing 
the functioning of the body in a holistic manner. Bad 
health and disease were seen as the body working in a 
non-harmonious way. Yin and yang were not in balance, 
qi was not flowing freely, and the five elements (wu xing) 
A          B                                C    
Figure 1. Chemical structure of quinine 
(A), mepacrine (B), and chloroquine (C). 
(Butler, 2019)
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were not in accord. An herb, or more likely a mixture of 
herbs, would restore harmony and balance, but this might 
work only in a human system and not in vitro or in a mouse 
model. The malarial parasite is difficult to culture in vitro. 
How closely was herbal prescribing in China inextricably 
bound to its distinctive medical system? Modern western 
phytotherapy has long since abandoned Galen’s theory 
of the four humors, but the parallel process in Chinese 
medicine has not occurred. A recent edition of the offi-
cial Chinese pharmacopoeia (Chinese Pharmacopoeia 
Commission 2015) uses the vocabulary of both Western 
pharmacology and traditional Chinese medicine. To 
believe that Chinese medicine is truly a ‘treasure house,’ 
do we have to accept what Sivin has called the ‘doctrines’ 
of Chinese medicine (Needham et al. 2000), or can we 
ignore them and just note what herbs were used, as done 
in Western herbalism?
Ackerknecht (1982) has argued that medical doctrines are 
a reflection of the society in which they were conceived. 
This is certainly true of Chinese medicine where, in the 
early centuries of the first millennium, there were many 
different medical doctrines. As the country became more 
united, efforts were made by scholars over the centuries 
to unify the doctrines. For example, The Yellow Emperor’s 
Classic of Internal Medicine (Huang Di nei jing su wen) was 
probably first written in the second century BCE and 
revised by different scholars until Wang Bing completed 
the work in the eighth century CE. To this day, it is still 
consulted by practitioners of Chinese medicine, which 
indicates the continuing importance of the doctrines. The 
Emperor’s Classic describes in elaborate detail the workings 
of yin/yang, the flow of qi, and balance of the wu xing.
Alongside medical theory existed the work of artisan 
physicians, who prescribed cures for the ills that beset 
humankind using mainly the herbs that grow so abun-
dantly in China, but also the distinctive therapies of 
acupuncture and moxibustion. Over the centuries, details 
of therapeutic herbs were collected and published in 
‘herbal compendia’ called ben cao. The earliest of the ben 
cao, The Divine Husbandman’s Classic of Materia Medica (Shen 
Nong ben cao jing) was completed in the first century BCE, 
and many others were produced over subsequent centu-
ries, reaching a climax in the posthumous publication of 
the Ben cao gang mu (Materia Medica Arranged according to 
Drug Description and Technical Aspects) by Li Shizhen in 1596 
CE. It lists over 1,800 medicinal herbs. To what extent are 
these remedies linked to the doctrines of Chinese medicine?
Needham, the great historian of all things scientific and 
medical in medieval China, was in no doubt about the 
link. He held that Chinese medicine was a body of knowl-
edge derived directly from empirical findings. Chinese 
scholars may have been deficient in relevant information 
because they lacked the tools for studying the human 
body, but what they asserted may contain ‘heralds’ of 
what modern science now understands about the human 
body. He saw Chinese medicine as a river flowing into 
an ocean that is ‘modern science.’ Other rivers include 
Greek and Ayurvedic medicine, but modern science is 
the unifying destination of them all. This view is fully 
expounded throughout Needham’s writings, as well as 
by Ho and Lisowski (1993). In opposition to this view, 
Unschuld sees little connection between the doctrines 
of Chinese medicine and the empirical prescribing to be 
found in the ben cao. In his discussion of the Huang Di nei 
jing su wen, he suggests that Section 74 is really the birth 
of prescription pharmacy. This section is a substantial 
one and the subject matter diverse (for a full discussion 
of Unschuld’s commentary on the Huang Di nei jing su wen, 
consult Unschuld 2003: 301-313). Interestingly, Section 
74 points out that it is not only the qualities of each herb 
in the remedy that makes the cure effective but also the 
combination and the location of the disease. It suggests 
there is a specific prescription for each diseased condition. 
Significantly, he remarks that “neither the yin-yang nor 
the five-agents doctrine are taken into account here” 
(Unschuld 2003: 312).
According to Unschuld, the doctrines of Chinese medicine 
were the speculations of scholars, detached and intel-
lectually curious, and they changed in step with cultural 
changes, but the cures were the province of artisans 
interested in earning a living by offering hope to suffering 
humankind. The cures remained remarkably constant. The 
compilers of the ben cao may have been scholars but they 
merely assembled material that had been unearthed by 
others. Unschuld sums up the dilemma for those trying to 
assess the value of Chinese medicine for the current time:
Are these foundations [the doctrines] required 
to understand Chinese medicine and practice it 
successfully, or can the substances and techniques 
used in Chinese medicine be effectively separated 
from their traditional background and explained 
in terms of Western science without becoming 
useless? (Unschuld 2003: 323)
His answer is an unequivocal yes, and one with which I 
concur. When the separation is made, one of the barriers 
to the use of the ben cao in drug discovery is removed 
and the valuable observations contained therein may be 
utilized in the modern treatment of disease by the process 
of extraction and biological testing. In a limited but 
valuable way, this has already been done. Ma huang, from 
Ephedra sinica, is mentioned in the comprehensive 
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Ben cao gang mu as treatment for impaired circulation and 
coughing. Its medicinal properties were rediscovered 
in the West by a Japanese chemist when ephedrine was 
extracted from the plant and used, initially, as a mydriate 
and later for the treatment of asthma and chronic pulmo-
nary disease (Amatsu and Kubota 1913). An account of the 
use of saltpeter (potassium nitrate, xiao shi) for the relief of 
the pain of angina reveals a perceptive piece of empirical 
prescribing that can be rationalized by recent discoveries 
in cardiac physiology (Butler and Moffett 2009). In both 
these cases, no reference is made to the doctrines of 
Chinese medicine, but valuable insight has been gained 
from information in a ben cao. What follows is an account 
of an even more spectacular example. 
 
Treatment of Malaria from the Ben Cao
Plants of the Artemisia genus are recommended in the 
ben cao for the treatment of intermittent fever. The two 
varieties mentioned are qing hao and huang hua hao. Hsu 
has shown that, strictly, Artemisia annua (from which a 
new antimalarial drug was eventually extracted in Project 
523) is huang hua hao and not, as commonly supposed, qing 
hao (A. apiacea) (Hsu 2006a). The researchers of Project 523 
used A. annua (Figure 2), but called it qing hao (sweet worm-
wood). Initial experiments in extracting from the plant 
some pharmacologically active material were unsuccessful 
for an interesting reason. Instructions for the use of the 
herb in the treatment of intermittent fever were given by 
the fourth century alchemist and physician Ge Hong.  
He writes:
Another recipe: qinghao, one bunch, take two sheng 
[0.4 litres] of water for soaking, wring it out, take 
the juice. Ingest it in its entirety. (Ge Hong, fourth 
century: 3.16)
As part of Project 523, a modern version of this was tried 
in which the leaves were immersed in hot water, the solid 
material filtered off, and the filtrate tested on a malarial 
murine model. No effect was observed. However, when a 
nonpolar solvent (petroleum ether) was used instead of 
hot water, material was extracted that proved to be highly 
toxic towards the malaria parasite in a murine model. The 
extract was named qing hao su (extract of qing hao) and 
later given the Westernized name of artemisinin. Further 
tests confirmed its effectiveness. It was purified and its 
chemical structure determined. The reason why the tradi-
tional route of administration, as described by Ge Hong, 
yielded a negative result was possibly the consequence of 
the now standard process of filtering off any solid material 
before testing the juice. Artemisinin forms in trichomes 
of the plant (Xiao et al. 2016) and soaking will release it 
into the water but it will not dissolve and therefore will be 
present in suspension. Hsu (2006b) has pointed out that Ge 
Hong instructs us to drink the juice without further refine-
ment. Once in the body, it can be solubilized by formation 
of a glucuronide—a frequently employed strategy in 
human physiology—to give artemisinin human metabolite, 
which is water-soluble, and this enters the bloodstream. 
Artemisinin does not appear to be solubilized by any of 
the other substances derived from the plant (Butler and 
Renton 2000). 
Chemical Structure of Artemisinin
Elemental analysis and nuclear magnetic resonance 
spectroscopy indicated that artemisinin is a sesquiterpene 
lactone with many oxygens present. The full structure 
(Figure 3) was revealed by an investigation using X-ray 
crystallography to show three fused alicyclic rings, one of 
which is 7-membered and, most surprisingly, one ring is 
spanned by a peroxide bridge. Peroxides are normally very 
unstable, but in artemisinin the peroxide group is quite 
stable, and artemisinin can be heated to 150 °C without 
decomposition. Although the mode of action of artemis-
inin is uncertain, it is probably the peroxide group that 
is responsible for its antimalarial activity. In the pres-
ence of a metal ion, such as the iron of hemoglobin, the 
oxygen-oxygen bond breaks giving rise, after a series of 
transformations, to carbon-centered radicals that destroy 
the malarial parasite (Butler et al. 1998; Meshnick 2002). 
All the three chemical features mentioned (fused alicyclic 
rings, a 7-membered ring and the peroxide bridge) are 
unusual in a plant natural product, and to find all three in 
the same material is astonishing. When news of artemis-
inin reached the West, there was considerable skepticism, 
particularly over the chemical structure, but the Chinese 
work was fully confirmed by other researchers.
Artemisinin is not an ideal drug as its low water solubility 
limits its bioavailability. Therefore, it has been chem-
ically modified to give an even better drug. The most 
successful modification is to convert it into the half ester 
of succinic acid to give artesunate (Figure 4) (Rosenthal 
2008). This is generally the form in which artemisinin is 
Figure 2. Artemisia annua. 
(Butler, 2015)
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used therapeutically, although there are other chemical 
modifications in use. Artesunate is water-soluble and can 
be used orally, rectally, intramuscularly, or intravenously. 
As is the case with quinine, parts of the molecule may not 
be necessary for its antimalarial action, and simpler mole-
cules with a trioxolane structure have been synthesized. 
One, arterolane, looked promising in in vitro testing but 
performed less well in clinical trials and has not challenged 
artesunate’s position (Posner et al. 1999). For the large-
scale production of artemisinin, A. annua is cultivated by 
small farmers in Africa and China, the leaves harvested and 
sent to factories where artemisinin is extracted and puri-
fied. High-yield plants have been developed by a process 
of selective breeding at the Centre for Novel Agricultural 
Products at the University of York. One of the difficulties 
with this system for the production of a product where 
the demand is about the same each year is that farmers 
are not willing to grow A. annua when the prices of other 
farm products are high. Production of the drug in a factory 
through biosynthesis involving genetically engineered 
yeast is under development. This has recently become 
quite successful and may provide a more reliable source. 
However, farm-produced artemisinin will probably remain 
an important source of the drug.
The Nobel Prize
In 2015, half the Nobel Prize in Physiology or Medicine was 
awarded for the discovery of the antimalarial properties of 
artemisinin. The other half of the Prize went to William C. 
Campbell and Satoshi Ōmura for work on parasitic worms. 
The Nobel Prize has to be awarded to a person, and one of 
the problems was that all the early papers on artemisinin 
were ascribed to groups rather than people. Thus, studies 
of its clinical potential, although published in the Chinese 
Medical Journal, were credited to the ’Collaborative research 
group on qinghaosu’ (Collaborative Research Group 
1979: 811-816), and its crystal structure was reported in 
Scientia Sinica and credited to ‘Qinghaosu Research Group’ 
(Qinghaosu Research Group 1980). However, investigation 
revealed Tu Youyou as the person largely responsible for 
the herbal work, and she went to Stockholm to collect  
the Prize.
Artemisinin Combination Therapy
Not long after artemisinin (which includes the original 
drug and all its chemical modifications used therapeuti-
cally) was first used as a treatment for malaria, it became 
clear that resistance to artemisinin could develop quite 
readily. In some parts of Southeast Asia, it was sold 
over the counter, and there was no attempt at ensuring 
compliance. Now that artemisinin is the frontline drug in 
the treatment of cerebral and vivax malaria, preventing 
resistance is a matter of great importance. To lose the drug 
because of resistance, as was the case with chloroquine, 
would be a major tragedy as no new antimalarial drug is 
waiting in the wings to take its place. 
The World Health Organisation (WHO) strongly recom-
mends that, in the treatment of uncomplicated cerebral 
malaria, artemisinin should always be given in combi-
nation with another antimalarial drug, as Artemisinin 
Combination Therapy (ACT) (Rehwagen 2006). An ACT is a 
combination of fast-acting, highly potent artemisinin with 
a slow-acting, less potent drug such as mefloquine, piper-
aquine, and even chloroquine. ACT is normally given over 
three days. Artemisinin kills the vast majority of the para-
sites by one mechanism, and the partner drug eliminates 
any remaining parasites over a much longer time period 
by another mechanism. It is thought that the two drugs 
protect one another from the development of resistance. 
However, combination therapy is expensive. Many poorer 
Figure 3. Chemical structure of artemisinin. 
(Butler, 2019)
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countries have tried to use a monotherapy to control 
malaria, but this is dangerous not only for that country 
but also its neighbors, as the artemisinin-resistant parasite 
does not recognize national boundaries. To avoid the use 
of monotherapies, the WHO has urged manufacturers to 
package the drugs in such a way that two components are 
given together. 
Much is known at a molecular level about the cause of 
drug resistance, and its development can be predicted by 
blood tests. In Western Cambodia, where resistance even 
to an ACT has developed, frequent tests would allow the 
ACT used in surrounding provinces to be changed before 
resistance has taken hold (Noedl et al. 2008). The success of 
combination therapy in the treatment of malaria suggests 
that it may be the way forward in the treatment of other 
diseased states, particularly those treated with antibiotics, 
but it is bound to be more expensive.
The Future of Drug Discovery
The era of small drugs—that is, molecules of below 400 
daltons—is coming to a close (Le Fanu 1999). Drugs like 
penicillin, aspirin, and the sulphonamides have made 
enormous improvements to human life, but most bioactive 
substances (which includes therapeutic drugs) are much 
larger molecules. Synthesizing large molecules with the 
hope that they will display drug action when tested is 
too demanding a program to undertake, as up to 1,000 
compounds may be needed to find the one that is active 
enough to submit for full clinical trials. However, natural 
products (i.e., substances that can be extracted from living 
sources such as plants, animals, and microorganisms) are 
a ready source of such compounds. We therefore look to 
living things, principally herbs, for possible therapeutic 
drugs, as they do the task of synthesis effortlessly, having 
been provided with enzymes to do the job. 
The constituents of the herbal extract are identified and 
tested for biological activity by a technique known as High 
Throughput Screening. This approach to drug discovery 
has proved successful in the past. For example, taxol or 
paclitaxel was found in an extract from the Californian 
yew tree during a massive screening of many thousands 
of natural products found in US plants and trees. This 
survey was financed by the US Government. Evidence of 
anti-cancer activity with the extract led to a more detailed 
study. From this, the first successful drug for the treat-
ment of ovarian cancer emerged. The effort involved in 
making this discovery was enormous, and government 
finance was required. Initially, the cost of taxol was costly, 
which does very little for the general health of human-
kind. Fortunately, some very clever chemistry involving 
chemical modification of a more abundant natural product 
reduced the cost substantially, and taxol is now generally 
available (see also Tidwell and Nettles 2019).
We are in a promising era for this type of drug discovery, 
as a number of sophisticated techniques for the separation 
of the complex mixtures obtained during extraction, and 
the chemical identification of the components are avail-
able. They mostly involve some form of chromatography 
linked to mass spectrometry. Moreover, in recent years it 
has been discovered that life can flourish under extreme 
Figure 4. Chemical structure of artesunate. 
(Butler, 2019)
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conditions, such as in hot springs or at very high pres-
sure at the bottom of the sea. Living things found in such 
places must have unique physiologies, possibly involving 
substances not found elsewhere and, possibly, new to 
chemistry. These are exciting possibilities to develop new 
drugs for conditions untouched by current therapies. 
If herbal medicine is used to select the plants studied, 
there is a sense in which some of the screening has been 
done already by countless herbalists over hundreds 
of years. The chances of success are higher but, disap-
pointingly, rarely is a new drug born in this way. Herbal 
medicine generally yields a weak drug or one no better 
than that already available. The discovery of artemisinin 
is a case when it did work, and worked spectacularly well. 
The herbs of a country with an unusual or little studied 
flora are of particular interest, especially if the medicinal 
values of the herbs have been recorded. However, for 
many herbalists, by extracting the active principle from 
the herb we are missing the point of herbal medicine 
(Butler and Keating 2011). They insist that it is the whole 
plant, rather than its components, that give it medicinal 
value. This proposition poses a considerable challenge 
when it comes to be tested experimentally as herbal 
extracts often vary in composition. It would be better if 
the constituents were identified and the pure compounds 
identified were paired, say, and the biological activity of 
each pair tested. There might be up to fifty biologically 
significant compounds in an herbal extract. Consequently, 
there would be many pairs, and the work would be both 
tedious and expensive but not impossible. If a pair showed 
enhanced therapeutic activity, this would suggest that 
there was some sort of synergy between the constituents 
of the pair. 
The success of ACT in both preventing resistance and 
enhancing the power of the drug, as described previ-
ously, does suggest that mixtures are better than single 
substances, and sometimes it is a case of ‘2+2 = 5.’ The 
effect of the combination is greater than the sum of its 
parts (see also Schwabl and van der Valk 2019). This is 
known to be true also for the treatment of tuberculosis 
and leprosy; malaria is in no way special. More experi-
mental work is required if this approach to chemotherapy 
is to be of general value. It is interesting to note that, in 
cinchona bark, there are two antimalarial alkaloids, as 
described previously. Possibly, they act synergistically to 
give the bark a curative power, which is greater than the 
small amount of quinine present in cinchona bark might 
have suggested. There is evidence of synergistic effects 
in the herbal remedies used for the treatment of malaria 
(Rasoanaivo et al. 2011).  
Conclusion
The isolation of artemisinin from Artemisia annua during 
the most testing of times, was an example of the triumph 
of perseverance and good scientific skills. Many people 
were involved in its success that it would have been fairer 
had others shared the Nobel Prize with Tu Youyou, which 
was not possible according to the rules. The story of the 
birth of artemisinin, when told in outline, is a simple one: 
a common herb, used for centuries by Chinese physicians 
for the treatment of fever, is now being used worldwide for 
the treatment of malaria, but that hides much of the good 
science for which the Nobel Prize was awarded. First, there 
was the problem of identifying malaria in the ben cao and 
choosing the correct species of Artemisia for study. Second, 
finding the correct procedure for extraction of the drug 
was a challenge. Drug action is enhanced by extraction. 
Since extraction concentrates the drug (and thus makes it 
more powerful), it might be seen as a process that paral-
lels, in modern chemotherapy, the potentiation gained 
by drug-drug interaction in biomedicine (Jia et al. 2009). 
Further potentiation, using the term in its more expansive 
sense, was possible once the chemical structure (mainly 
from nuclear magnetic resonance spectroscopic and X-ray 
crystallographic studies) had been elucidated. This allowed 
chemists to see how the molecule could be modified to 
increase its bioactivity by making it more water-soluble. It 
turned out that the most successful way of achieving that 
was to convert artemisinin into the half ester of succinic 
acid, to give artesunate. The final step in potentiation 
was setting up the regimens for artemisinin combination 
therapy. The drug is potentiated so that resistance will not 
diminish its power. The attempt at further potentiation by 
making simpler molecules that contain just the essential 
part of the artemisinin molecule has been unsuccessful 
so far. It is perhaps stretching the meaning of the term 
potentiation somewhat, but promising work on the 
industrial synthesis of artemisinin, which should reduce 
its cost, could be considered part of that process. Designing 
new and costly drugs for diseases that are endemic in poor 
parts of the world is valueless. Instead, basing a drug on an 
existing herbal remedy that has been potentiated is much 
more likely to come up with an affordable drug. Many 
thousands throughout the world who owe their lives to the 
development of ACT should be grateful to Tu Youyou and 
Project 523. 
There is one remaining matter for consideration. For the 
last century or so, one of the aims of pharmacology has 
been to extract from herbs the active principle and, as new 
herbs are examined, this is still important. However, it is 
just as important to examine other substances present in 
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the herb in order to understand better how potentiation 
may be achieved by drug-drug interactions and synergy. 
The presence of substances in the herb, other than the lead 
compound, may help in avoiding the build up of resistance. 
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